Organization
Istituto Europeo di Oncologia IRCCS
3 abstracts
Abstract
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.Org: Agomab Spain, LMU Munich, The Jikei University School of Medicine, Co-ordinating Center for Clinical Trials of the Philipps-University of Marburg, Seoul National University Hospital,
Abstract
Unfavourable carcinoma of unknown primary (CUP) with gastrointestinal profile: A retrospective study.Org: Istituto Europeo di Oncologia IRCCS, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology (IEO),
Abstract
Clinical and radiological criteria for candidate patients with small bowel neuroendocrine neoplasms (SB-NEN) for minimally invasive surgery: A single-centre experience.Org: Istituto Europeo di Oncologia IRCCS, European Institute of Oncology, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, European Institute of Oncology (IEO) IRCCS,